Interviews

Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.

Debra Patt, MD, PhD, MBA, MPH, discusses AI adoption, administrative burden, and strategies to streamline prior authorization in oncology.

J&J's Oncology Care Index finds a systems problem, not a confidence gap, in community oncology, Mahadi Baig, MD, says.

Bundled payment models offer employers and community oncology practices greater cost predictability while improving patient access, Baird said.

Jeff Hunnicutt emphasized vetting prior authorization vendors, scaling beyond single use cases, and AI's potential to streamline workflows.

Rosa Novo discusses tailoring cancer benefits to workforce needs, improving access and prevention, and return-to-work support.

Inebilizumab's twice-yearly CD19 dosing directly targets antibody-producing cells; trial enrollment used disease activity, not treatment failure.

Keith Kaye, MD, MPH, explains how shorter antibiotic courses and optimized dosing help balance treatment efficacy against C. diff risk.

Employers can advance patient-centered oncology care through proactive benefits, quality data, navigation, and tailored support, Amanda Green, MPH, said.

Swarup Kumar, MD, emphasizes that preparation is central to positive outcomes and includes patient education and early intervention when needed.

Real-world COPD data from ERS 2026 support RSV vaccination, but Jorgen Vestbo, MD, says cost remains the biggest barrier to wider uptake.

Timely dupilumab initiation after a severe asthma exacerbation lowered costs vs delayed treatment, ERS 2026 data show.

Jason Pogue, PharmD, breaks down which antibiotic classes carry the highest C. diff risk and why treatment duration matters just as much.

Lalan Wilfong, MD, discusses how model assumptions, cohort design, and risk adjustment shape performance and accountability in value-based oncology.

During Suicide Prevention Month, UPMC experts discuss how lived experience, peer support, and connection strengthen suicide prevention.

Francesca Polverino, MD, PhD, says COPD care still lacks a true precision medicine approach.

Keith Kaye, MD, MPH, breaks down the institutional gaps, from antibiotic overuse to hand hygiene fatigue, that let Clostridioides difficile persist.

AI tools can ease administrative burden in community oncology, but practices face adoption, security, compliance, bias, and error concerns.

A Danish cohort study found 100% RSV vaccine effectiveness in COPD, but Jorgen Vestbo, MD, urges caution interpreting real-world results.

Ann Marie Navar, MD, PhD, on enlicitide's 60% LDL reduction, less than 50% ApoB lowering, fasting dosing rules, and how it compares with inclisiran.

Yet H. Khor, MD, PhD, explains why a 20% emphysema threshold on CT imaging may better define combined PF and emphysema in fibrotic ILD.

Tozorakimab targets IL-33 upstream of TH2 pathways, cutting COPD exacerbations up to 34% in former smokers, Frank Sciurba, MD, explained.

Laura Fabbri, MD, says patient wishes should guide care decisions in IPF and lung cancer overlap.

Francesca Polverino, MD, PhD, says COPD exacerbation severity lacks a clear definition, complicating GOLD's escalation criteria.

Yet H. Khor, MD, PhD, explains why the CPFE index can't replace CT imaging but may help triage which patients need scans.

Policy changes could have the greatest impact on transplant equity, explains hematologic oncologist Karilyn Larkin, MD.

Trejeeve Martyn, MD, shares why finerenone belongs on formulary, and how pharmacist-led access models can work in smaller health systems.

Follow-up length varied by subgroup in the MINT trial, but inebilizumab cut exacerbations and rescue therapy use consistently.